Similar articles

• Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease.

  García-Martín P, Alarcón-Payer C, López-Fernández E, Moratalla L, Romero A, Sainz J, Ríos R, Jurado M. García-Martín P, et al. Ann Pharmacother. 2015 Sep;49(9):986-94. doi: 10.1177/1060028015593369. Epub 2015 Jul 9. Ann Pharmacother. 2015. PMID: 26160968
• Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.

  Solomon SR, Sanacore M, Zhang X, Brown S, Holland K, Morris LE, Bashey A. Solomon SR, et al. Biol Blood Marrow Transplant. 2014 Nov;20(11):1828-34. doi: 10.1016/j.bbmt.2014.07.020. Epub 2014 Jul 23. Biol Blood Marrow Transplant. 2014. PMID: 25064745 Clinical Trial.
• Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.

  Wolff D, Wilhelm S, Hahn J, Gentilini C, Hilgendorf I, Steiner B, Kahl C, Junghanss C, Hartung G, Casper J, Uharek L, Holler E, Freund M. Wolff D, et al. Bone Marrow Transplant. 2006 Sep;38(6):445-51. doi: 10.1038/sj.bmt.1705454. Bone Marrow Transplant. 2006. PMID: 16951692 Clinical Trial.
• Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment.

  Holler E. Holler E. Best Pract Res Clin Haematol. 2007 Jun;20(2):281-94. doi: 10.1016/j.beha.2006.10.001. Best Pract Res Clin Haematol. 2007. PMID: 17448962 Review.
• Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease.

  Wolff D, Steiner B, Hildebrandt G, Edinger M, Holler E. Wolff D, et al. Curr Pharm Des. 2009;15(17):1974-97. doi: 10.2174/138161209788453158. Curr Pharm Des. 2009. PMID: 19519437 Review.